Effectiveness And Safety Of Dalteparin In Patients With Acute Coronary Syndromes Without ST Elevations In Clinical Practice

• Number of Participants With Death or Myocardial Infarction (MI) [ Time Frame: Baseline to 28 days after last dose of study drug ] [ Designated as safety issue: No ]
• Number of Participants With Major Bleeding Events [ Time Frame: Baseline to 28 days after last dose of study drug ] [ Designated as safety issue: Yes ]
  Bleeding events were considered major if, accompanied by a decrease in hemoglobin of more than or equal to 2 grams/deciliter (g/dL) in connection with clinical symptoms; a transfusion was required; bleeding led to interruption of treatment or death; or intracranial bleeding.
• Number of Participants With Minor Bleeding Events [ Time Frame: Baseline to 28 days after last dose of study drug ] [ Designated as safety issue: Yes ]
  Bleeding events like hematuria, wound hematoma or injection site hematoma which did not fulfill the criteria for a major bleeding episode were classified as minor bleeding.

• Death and myocardial infarction [ Time Frame: end of index hospitalization ] [ Designated as safety issue: No ]
• Minor bleeding [ Time Frame: end of index hospitalization ] [ Designated as safety issue: Yes ]
• Major bleeding [ Time Frame: end of index hospitalization ] [ Designated as safety issue: Yes ]

• Stroke [ Time Frame: end of index hospitalization ] [ Designated as safety issue: Yes ]
• Cardiac arrest - resuscitated [ Time Frame: end of index hospitalization ] [ Designated as safety issue: Yes ]
• Heparin induced thrombocytopenia [ Time Frame: end of index hospitalization ] [ Designated as safety issue: Yes ]

To collect data on safety and effectiveness of dalteparin in the management of non-ST segment elevated acute coronary syndromes in nursing home patients who will be treated conservatively (without percutaneous corornary intervention [PCI] or coronary artery bypass graft [CABG] within 48 hours).

t

Patients management of non-ST segment elevated acute coronary syndromes in nursing home who will be treated conservatively (without percutaneous corornary intervention [PCI] or coronary artery bypass graft [CABG] within 48 hours).

Inclusion Criteria:

• Male or female patients of 18 years or more presenting with chest pain will be potentially eligible for inclusion in the study if they satisfy the criteria for unstable coronary artery disease per the investigator's routine practice and have received at least one injection of Fragmin (dalteparin sodium) as part of routine clinical practice and is expected to be treated conservatively (without PCI or CABG within 48 hours) during the index hospitalization.
• Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.

Exclusion Criteria:

• Patients who are contraindicated to receive this agent per the local approved prescribing information.